Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial

CUMBERLAND PHARMACEUTICALS INC

High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.
Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.
Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.
End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.